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Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53 S35grade 3-4 aGVHD post PBSC alloHCT was 14% and 10% in the
Caucasians and Japanese, respectively (Figure 1B). In
multivariate analysis, the interaction term between race and
graft source was not signiﬁcant in any of the models,
indicating that the impact of race on outcomes does not
differ according to graft source. The risk of grade 3-4 aGVHD
was signiﬁcantly lower in Japanese compared to Caucasians
(HR 0.74, 95% CI 0.57-0.96), which resulted in lower risk of
non-relapse mortality (NRM) in Japanese compared to
Caucasian patients (HR 0.69, 95% CI 0.54-0.89). The risk of
relapse was also lower in Japanese compared to Caucasian
patients (HR 0.75, 95% CI 0.63-0.89). Lower risk of NRM and
relapse resulted in lower overall mortality rates in Japanese
compared to Caucasians (HR 0.70, 95% CI 0.59-0.83). The
risk of grade 3-4 aGVHD was signiﬁcantly higher in PBSC
compared to BM alloHCT recipients (HR 1.63, 95% CI 1.20-
2.20), which resulted in higher NRM (HR 1.31, 95% CI 1.04-
1.65) in PBSC compared to BM alloHCT recipients.
Conclusions: Irrespective of graft source, the risk of severe
aGVHDwas lower in Japanese patients, which resulted in the
lower risk of NRM. The risk of severe aGVHD was higher in
the PBSC alloHCT recipients, which resulted in the higher risk
of NRM.14
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Background: Extracorporeal photopheresis (ECP) modulates
host antigen presenting cells implicated in graft versus host
disease (GVHD) development. Incorporation of ECP into a
reduced intensity conditioning (RIC) regimen may prevent
acute (a) and chronic (c) GVHD.
Methods: Data were collected from Tufts Medical Center
BMT and Center for International Bone Marrow Trans-
plantation Registry (CIBMTR) databases. All patients who
received PPTconditioning (ECP on days -6 and -5, Pentostatin
on days -4 and -3, 600 cGy TBI on days -2 and -1) at Tufts
between 10/1999e12/2013 were included. Cyclosporine and
methotrexate were used for GVHD prophylaxis.
Results: 206 pts (56% male) received PPT. Median age was
53 (19-70) with 45% > 55. Median time from diagnosis to
transplant was 17 months (1-180). 59% had matched
related donors. Marrow was the stem cell source in 72%.
8% of transplants were mismatched at 1 antigen. Most
common indications were Acute Myeloid Leukemia (AML)
(35%), Myelodysplastic Syndrome (16%) and Non-Hodgkin
Lymphoma (12%). Of the 73 pts with AML, 33% were in
ﬁrst complete remission (CR1), 18% were in a second or
greater complete remission (CR 2) and 49% had active
disease.ving PPT Conditioning by Diagnosis.
Figure 2. Overall Survival of AML Patients by Remission Status.
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were 17 and 19 days, respectively. Grade 3-4 aGVHD occurred
in 20% and 14% in the total cohort and AML subset respec-
tively. cGVHD developed in 54% (17% extensive stage) and
35% (8% extensive stage) of pts in the total cohort and AML
subset respectively.
The 5 year OS for the entire cohort was 29% [95% CI (23%-
36%)], and varied by diagnosis (Fig 1). NRM at 100 days was
17% [95% CI (13%-23%)].
On univariate analysis of the entire cohort, only 1-antigen
mismatch [HR 1.96, p-value¼0.01] and KPS<80 [HR 10.66, p-
value <0.001] were associated with worse OS. In the AML
cohort, active disease at HSCT (HR 2.43 p¼0.001), failure to
engraft (HR 4.84 p<0.001), and grade 3-4 aGVHD (4.08
p<0.001) were associated with worse OS. In multivariate
analysis after stepwise selection, advanced age (aHR 1.36,
p¼0.04), active disease (aHR 2.46, p-value¼0.003) (Fig 2),
engraftment syndrome (aHR 43, p¼0.001) and grade 3-4
aGVHD (aHR 5.23 p<0.001) were associated with worse OS.
Conclusions:We report over a decade of experiencewith the
PPT regimen. OS and low NRM are similar to other reported
RIC regimens despite high rates of active disease at HSCT.
Rates of severe acute and extensive chronic GVHD were low.
PPT remains a viable regimen for pts not eligible for mye-
loablative conditioning.15
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Background: A compromised immune system of Hemato-
poietic Cell Transplantation (HCT) recipients early aftertransplantation renders them vulnerable to a heightened
risk of reactivation of otherwise latent viral infections. Un-
controlled reactivation of Epstein-Barr virus (EBV) is one of
such events that can culminate into post-transplant lym-
phoproliferative disorder (PTLD), a complication associated
with high risk of mortality. Recovering within weeks after
transplantation and being ﬁrst in the line of defense against
viral infections, natural killer (NK) cells are deemed
important in the immune surveillance against the reac-
tivation and complications of EBV. Their role however re-
mains elusive. The complexity of NK cell response is a
function of a series of activating and inhibitory cell surface
receptors known as Killer Immunoglobulin-like Receptors
(KIR), which sense perturbations in HLA expression after
viral transformation of the target cell. Here, we set out to
determine whether and how KIR gene repertoire of HCT
donors and/or recipients inﬂuences the development of
PTLD after allo-HCT.
Study Design: KIR gene repertoires of 356 HLA-matched
donor-recipient pairs of ﬁrst allo-HCT and 50 healthy in-
dividuals were determined by Luminex based rSSO method.
The KIR genotypes were classiﬁed into AA and B/x genotypes.
Presence or absence of one or more haplotype-B deﬁning KIR
genes further identiﬁed genotypes for centromeric (Cen) and
telomeric (Tel) parts of the KIR locus. PBMNCs from 50 KIR-
genotyped healthy volunteers were stimulated with EBV-
transformed cells to enumerate EBV-induced NK cell
response (degranulation and/or IFNg production) as a func-
tion of KIR gene distribution using a multicolor ﬂow
cytometry-based assay. Effect of KIR gene repertoires on
development of PTLD was analyzed using binomial
competing risks regression statistics.
Results: Donor telomeric A motifs (Tel-A, KIR3DL1+ve-
KIR2DS4+ve; KIR3DS1/2DS1+/-ve), strongly protected against
PTLD (p¼0.0002, SHR¼0.21; Figure 1A). The protection of
donor Tel-A motifs against PTLD shows a dose dependent
effect as cumulative incidence of PTLD in HCT recipients
receiving graft from donors carrying two Tel-A motifs, one
Tel-A motif and no Tel-A motif was 6%, 11% and 19%
respectively. Further, the numbers of EBV induced
functional NK cell subsets were signiﬁcantly higher in
individuals with than without KIR genotypes containing
Tel-A motifs (Figure 1B).
